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Background
Left ventricular assist devices (LVAD) have been widely used in the clinical. However, 
control strategies are still a significant challenge for researchers. The rotational speed of 
the rVAD needs to be regulated carefully in response to the change in blood demands of 
patients. Therefore, several control strategies have been designed. Giridharan et al. [1] 
proposed a physiological controller using the mean differential pressure between the left 
ventricle and the aorta to regulate pump speed. Boston et al. [2] designed a hierarchical 
controller to remain the pulsatility of the pump flow signal by the pump speed. Arndt 
et al. [3] proposed full or partial assistance mode of LVAD by the gradient of differen-
tial pressure pulsatility to classify two specific operating modes. Wu et al. [4] proposed 
a physiological adaptive controller by calculating the change of peripheral resistance 
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according to intrinsic pump parameters (pump speed and current waveform) to regulate 
the pump speed. Chang et al. [5] reported a global sliding mode controller for an intra-
aortic pump to improve the robustness of the controller. Moscato et  al. [6] indicated 
a control strategy using the afterload of the left ventricle derived from left ventricular 
pressure and blood flow to maintain the afterload of the left ventricle at a level. Besides 
the control strategies that directly utilize the left ventricular pressure, flow rate and 
derived variables as the control variables, there exits another kind of control approach. 
For instance, Vollkron et al. [7] based on linear mapping of the relationship between the 
heart rate and rotational speed to regulated the pump speed. Similarly, Song et al. [8] 
studied the difference in varied support modes of LVAD on cardiovascular system. Gao 
et al. reported a fuzzy logical controller and a model free adaptive controller (MFAC) to 
improve the control accuracy [9–11]. Both control strategies used the heart rate as the 
control variable. The aim is to maintain the heart rate of patients within a normal range. 
To promote the heart function recovery, a baroreflex sensitivity controller has been 
reported [12]. In this control strategy, the baroreflex sensitivity (BRS) has been used as 
the control variable. An extreme search algorithm was designed to find the maximum 
value of the BRS. Then the optimal operating point of the BJUT-II VAD was calculated 
according to the BRS.
The above-mentioned strategies have been verified in numerical simulation and 
in vitro, and the results demonstrate that they can regulate the pump according to the 
change in metabolic demands of their patients. According to Birks’s report [13], the 
combination of continuous-flow (CF) circulatory support and pharmacological therapy 
can significantly improve the heart function recovery and the survival rate. Mahmood 
et al. [14] established a model that combined the cardiovascular system, LAVD and the 
pharmacodynamics model of sodium nitroprusside. Although studies show the impor-
tance of the studies on the interaction between LVAD support and pharmacological 
therapy, the effect of the pharmacological therapy, such as the angiotensin-converting 
enzyme inhibitor (ACEI), on the performance of the control strategy of LVAD is neglect 
by most researchers.
BJUT-II VAD is a novel rVAD, which is developed by the artificial heart research 
group at Beijing University of Technology [15]. Due to it avoid damaging myocardium 
and eliminate the percutaneous wires, it is specially fit for long-term support. Therefore, 
it is important and necessary for BJUT-II VAD to study the interaction between phar-
macological therapy and LVAD support under varied control strategies. In the field of 
pharmacological therapy, captopril which is an angiotensin-converting enzyme inhibitor 
(ACEI) represents a significant therapeutic advance in the treatment of congestive heart 
failure [16]. It principally acts by interfering with the local and generalized production of 
angiotensin II, a hormone that, apart from its vasoconstriction power, also promotes, via 
aldosterone stimulation, an increased sodium and water retention [17]. Therefore, cap-
topril plays a significant value in clinical treatment of HF.
To achieve this aim, according to the guidelines for the treatment of the acute and 
chronic heart failure, captopril that is a kind of ACEI is chosen to study the effect of 
pharmacological therapy on the control strategy of BJUT-II VAD. To mimic the effect 
of the captopril on the hemodynamic parameters, a pharmacokinetic model of captopril 
has been established. Then, a combination model of the cardiovascular system model 
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and the pharmacokinetic model of captopril was established. Two control strategies of 
BJUT-II VAD, which chose the heart rate (HR) [10] and blood assist index (BAI) [18], are 
chosen as the target control strategies to evaluate the performance of them.
Methods
The design of pharmacokinetic model of captopril
In response to Kelly’s report, the pharmacokinetic model of captopril is consistent with 
the character of two-compartment model. Hence, the structure of pharmacokinetic 
model of captopril is shown in Fig. 1a. In this model, it is assumed that the drug delivery 
is by the first-order pharmacokinetics. According to the theory of pharmacokinetic, the 
model can be represented by Eqs. (1) to (3).
where X, X1 and X2 is the dose of captopril tables, the dose of captopril in plasma and 
the dose of captopril in tissues, respectively. k, k12, k21 and k10 represent the coefficients 













Fig. 1 The pharmacokinetic model of captopril. a is the scheme of the pharmacokinetic model of captopril; 
b is the waveform of the model. The data of measured concentration of captopril is derived from Ref. [19]
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through tissue to plasma and the coefficient of plasma–drug clearance per unit volume, 
respectively. Then, the plasma–drug concentration is derived from (1) to (3) as:
where C1(t) is the plasma-drug concentration, F represents the absorbed fraction, V1 
represent the apparent volume of distribution.
According to clinical data of plasma-drug concentration [19], shown in Table  1, the 
parameters in (4) are determined by using data fitting algorithm. Then, the pharmacoki-
netic model of captopril is derived as:
To verify the accuracy of (5), a comparison between the clinical data (measured 
concentration of captopril) and the data derived from (5) (computed concentration 
of captopril) is conducted. The result is shown in Fig. 1b. It demonstrates that Eq.  (5) 
can accurately reflect the relationship between time and plasma-drug concentration of 
captopril.
The sigmoid Emax model [20] is chosen as the pharmacodynamic model of captopril, 
denoted as:
where E(C) is the effect of the captopril in the current concentration, Emax represents the 
maximum effect, CE50 is the concentration in where the captopril generates their 50% 
maximum effect, c represents the concentration of captopril, s is the steepness param-
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Table 1 The clinical data of  the mean plasma-drug concentration of  captopril (ng/ml) 
obtained from 18 patients who oral captopril (50 mg)
The data is derived from reference [19]
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The combination model
In order to evaluate the effect of captopril on control strategy of BJUT-II VAD, a com-
bination model is designed. In this combination model, the pharmacokinetic model of 
captopril is coupled with a cardiovascular system model. Figure 2 shows the complete 
electric circuit analogy of the combination model. The model comprises the left atrium, 
the active left ventricle, BJUT-II VAD, the peripheral circulation system and the control-
ler for the peripheral resistance. The controller adjusts the peripheral resistance accord-
ing to the output of the pharmacokinetic model and pharmacodynamics model [21], 
denoted as Eq. (7).
where R0 represents the peripheral resistance without taking captopril; E(C), which is 
the output of Eq. (6), is the drug effect of captopril; Rs represents the peripheral resist-
ance at current plasma-drug concentration.
The combination model is described as a nonlinear time-varying lumped parameter 
model, which is described by a set of differential equations as:
(7)Rs = R0(1− E(C))
































































Fig. 2 The mathematic model of combination model
Page 404 of 410Gu et al. BioMed Eng OnLine 2016, 15(Suppl 2):123
where γ(x) represents the ramp function. The γ(x) is used to mimic the unidirectional 
properties of aortic valve and mitral valve.
where C is the compliance; R is the resistance properties; the left ventricle is represented 
by the time-varying compliance C(t) = 1/E(t). The details of the cardiovascular system 
model is reported in Refs. [12, 20].
The control strategies of the BJUT‑II VAD
The BAI control strategy of the BJUT‑II VAD
The energy distribution between the LVAD and native heart is indicated by BAI [11], 
which is a ratio of power of LVAD and total power of the cardiovascular system, denoted 
as the Eq. (8).
where U(t) is the power supply voltage of the LVAD, I(t) is the winding current of the 
pump, η(ω) represents the efficiency of the pump, which is a function of the rotational 
speed of the pump ω. P(t)aop is the waveform of aortic pressure, and F(t)aop denotes the 
waveform of the blood flow in the aorta, Tc represents the cardiac cycle; BAI(ω) repre-
sents the blood assistant index, whose unit is %.
Figure 3a proposed BAI control strategy. BAIm is assessed and calculated by the pres-
sure (Paop(t)), blood flow (Faop(t)) of aorta, the power supply voltage of pump (U(t)) and 
the winding current of pump (I(t)) at each heart cycle. Then BAIm and BAId are used 
as control input to adjust the rotational speed of the pump. The value of parameters is 
reported in Ref. [18] and the same method is used in the published paper.
(12)γ (ε) =
{
0 ε ≤ 0











Fig. 3 The scheme of control strategies of BJUT-II VAD. a The scheme of the BAI control strategy; b The 
scheme of HR control strategy
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The HR control strategy of BJUT‑II VAD
According to previous researches of our group, HR indicates the change in metabolic 
demand. Hence, the HR is chosen as the control variable in the HR control strategy. 
The aim of this control strategy is to maintain the HR in a normal range. The scheme of 
the HR control strategy is shown in Fig. 3b. The measured HR (HRm) is estimated from 
ECG signal. The details and the value of the parameters of the control strategy have been 
reported in Ref. [10].
Results
In order to evaluate the effect of the captopril on the performance of the control strategy, 
three numerical simulations are conducted. In the first simulation, the captopril is added 
into the combination model at 2  s. The accuracy of the combination model without 
BJUT-II VAD is tested. In the second simulation, the HR control strategy is employed 
to regulate the BJUT-II VAD. The captopril is added into the combination model at 8 s. 
The dose of captopril is 50 mg. In the third simulation, the BAI control strategy is used 
to adjust the pump. The captopril, whose dose is 50 mg, is added into the combination at 
10 s.
Figure 4 shows the waveform of left ventricular pressure (LVP), aortic pressure (AOP), 
blood flow, peripheral resistance and plasma–drug concentration of captopril without 
VAD support. From this figure, it is seen that aortic pressure and blood flow are consist-
ent with the clinical data. When the plasma–drug concentration of captopril increases, 
the peripheral resistance decreases accordingly. That means the combination model can 
mimic the effect of the captopril on the hemodynamics of cardiovascular system.
To visualize the performance of the HR control strategy, arterial pressure (AP), blood 
flow and rotational speed are plotted in Fig. 5. The first panel of Fig. 5 is the curve of 
arterial pressure; the second panel of Fig. 5 is the waveform of blood flow; the last panel 
of Fig.  5 shows the curve of rotational speed of the pump. It is seen that, when the 
plasma–drug concentration increases, the arterial pressure decreases accordingly. And 
Fig. 4 The response of the LVP, AOP, blood flow, peripheral resistance and concentration of captopril without 
BJUT-II VAD
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the change in arterial pressure leads the heart rate increase (Fig. 6). Then, the rotational 
speed of the pump increased from 5500 to 6300 rpm to compensate the change in heart 
rate (Fig. 5 last panel).
The response of the BAI control strategy to the captopril is plotted in Figs. 7 and 8. The 
first panel of Fig. 7 is the curve of arterial pressure; the second panel is the waveform of 
blood flow and the third panel is the rotational speed of the pump. The change in BAI 
along with the plasma–drug concentration of captopril is shown in Fig. 8. It is seen that 
along with the increase of plasma–drug concentration, the mean arterial pressure reduce 
from 110 to 100 mmHg. This phenomenon leads the BAI decrease from 60 to 55%. Then, 
the BAI controller increases pump speed to compensate the change in BAI. After 5 s, the 
BAI track its desired value. During this period, the blood flow also increases because of 
the increase of rotational speed and the decrease of peripheral resistance.
Fig. 5 The response of arterial pressure, blood flow and rotational speed supported by HR controller
Fig. 6 The response of the heart rate and plasma–drug concentration of captopril
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Discussion
With the development of LVAD, the “long-term support” has been paid more and 
more attention by many researchers. In long-term support, the combination of rVAD 
and pharmacological therapy can significantly improve the heart function recovery and 
the survival rate of heart failure patients [22]. For instance, Birks et al. [13] report their 
recent experience using the combination of continuous-flow (CF) circulatory support 
and pharmacological therapy to treat advanced heart failure in patients requiring LVAD 
support. The results demonstrate that there is about 60% study cohort met criteria for 
LVAD explantation and about 50% who survived the perioperative period demonstrated 
sustained recovery over 56–1112  days of follow-up. In 2006, Harefield recovery study 
demonstrates that data regarding combined pharmacological and mechanical support 
were available [23]. The authors reported that 75% of patients receiving clenbuterol 
could undergo LVAD explantation. Therefore, the combination of the pharmacological 
therapy and LVAD is significantly important for long-term support. And the study of the 
Fig. 7 The response of arterial pressure, blood flow and rotational speed supported by BAI controller
Fig. 8 The response of the BAI and plasma–drug concentration of captopril
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effect of pharmacological therapy on the performance of control strategy of LVAD is the 
basis of design combination therapy.
The critical of evaluating the control strategy of LVAD is to verify its response to the 
changing in hemodynamic parameters. However, traditional way is to set the variation 
of hemodynamic parameters by operator’s idea. For instance, in Ref. 13, the peripheral 
resistance is changed by step function. That is the peripheral resistance in this work 
occurred jump. In Karantonis’ report, the peripheral resistance is set to change in accord-
ance with linear law [24]. However, in clinical, the hemodynamic parameters are usually 
changed by drugs. For instance, the captopril has been widely used to reduce the periph-
eral resistance. Therefore, on one hand the pharmacokinetic model is introduced into the 
evaluation of control strategy of rVAD can provide a more realistic hemodynamic status 
for the evaluation of control strategy. On the other hand, it can give doctors more intui-
tive guidance on how to manage the pharmacological therapy under rVAD support.
Figure 4 shows the waveform of left ventricular pressure (LVP), aortic pressure (AOP), 
blood flow and the peripheral resistance. It is seen that, along with the increase of 
plasma-drug concentration of captopril, the peripheral resistance is reduced accordingly. 
Because of the decrease of peripheral resistance, the blood flow increase accordingly 
(Fig. 4 second panel). That means the captopril can reduce the afterload of the left ven-
tricle, which is consistent with the clinical data. Hence, combination of rVAD and cap-
topril to treat advanced heart failure is significant. Moreover, the results of simulation 
demonstrate that the combination of pharmacokinetic model and the lumped param-
eter model of cardiovascular system can mimic the effect of drug on the hemodynamics 
of cardiovascular system. This is a novel method for researchers to evaluate the perfor-
mance of control strategy.
From Fig. 6, it is seen that when the concentration of captopril increase, the heart rate 
will increase accordingly. That because the captopril reduces the afterload of the left 
ventricle, which will reduce the arterial pressure (Fig. 5 first panel). According to Chang 
et  al. [10], the heart rate in the cardiovascular-baroreflex system is regulated by the 
baroreflex system. When the arterial pressure decreases, the frequency of spikes in the 
afferent fibers will reduce. The sympathetic nerves and vagal fibers choose the frequency 
of the spikes in the afferent fibers as the input. When the frequency reduces, the sympa-
thetic will be activity and on the contrary, the vagal will be inhibition. This phenomenon 
results in the increase of the heart rate.
Figure 8 plots the waveform of BAI and plasma–drug concentration of captopril. It is 
seen that along with the increase in plasma–drug concentration of captopril, the BAI 
will reduce. That because captopril will reduce the peripheral resistance. This will reduce 
the differential pressure of the BJUT-II VAD and change the energy distribution between 
the native heart and BJUT-II VAD.
The above-mentioned simulation results demonstrate that the captopril can affect the 
hemodynamics of cardiovascular system by changing the peripheral resistance. Due to the 
control strategy of rVAD chooses the hemodynamic parameters as the control variables to 
evaluate the metabolic state of patients; the captopril will directly affect the performance of 
the control strategy. Hence, it is important for researchers to evaluate the performance of 
control strategy under pharmacology therapy. The combination model established in this 
work provides a novel method to achieve this aim. Moreover, both of the control strategies 
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evaluated in this work can respond to the change in hemodynamic parameters and main-
tain the cardiovascular system in a normal range. That means the control strategies evalu-
ated here can be applied for patients who under pharmacological therapy.
In this work, the pharmacokinetic model is established based on the single dose phar-
macokinetic model therapy. According to the guidelines for the treatment of the acute 
and chronic heart failure, the captopril will be taken repeatedly. Hence, the multi-dose 
pharmacokinetic model should be established. Also, Viecili [25] reported that captopril 
alone produced an increase in cardiac index and a decrease in systemic vascular resist-
ance and pulmonary capillary wedge pressure. In the future, pressure of pulmonary can 
be considered for captopril.
According to the pharmacokinetic theory, the individual differences of pharmacoki-
netic parameters are very obvious. Hence the researchers should determine the phar-
macokinetic parameters of patients’ own, and established the personalized combination 
model for patient. Then the personalized combination therapy strategy will be designed 
based on the combination model. This work will be conducted in the future.
Conclusion
The pharmacokinetic model of captopril, based on clinical data, is established. The com-
bination model that includes a cardiovascular system model and the pharmacokinetic 
model is proposed. The simulation results demonstrate that the combination model 
can reflect the effect of captopril on the hemodynamics of cardiovascular system. The 
BAI control strategy and HR control strategy of BJUT-II VAD are employed to evaluate 
the effect of pharmacological therapy on performance of control strategy. The results 
showed that captopril could affect the performance of BAI control strategy and HR 
control strategy. Both of control strategies can respond to the change in hemodynamic 
parameters caused by captopril. The combination model proposed here provides a novel 
method for researchers to evaluate the performance of rVAD controller.
Declarations
Authors’ contributions
YZ and YC were responsible for the design and overall investigation. KG and BG were responsible for computational 
modeling, statistical data analysis. All authors (1) have made substantial contributions to conception and design, or 
acquisition of data, or analysis and interpretation of data; (2) have been involved in drafting the manuscript or revising it 
critically for important intellectual content; and (3) have given final approval of the version to be published. Each author 
has participated sufficiently in the work to take public responsibility for appropriate portions of the content. All authors 
read and approved the final manuscript.
Acknowledgements
This work was partly sponsored by the National Natural Science Foundation of China (Grant Nos. 11572014, 91430215).
Competing interests
The authors declare that they have no other competing interest.
About this supplement
This article has been published as part of BioMedical Engineering OnLine Volume 15 Supplement 2, 2016. Compu-
tational and experimental methods for biological research: cardiovascular diseases and beyond. The full contents of 
the supplement are available online http://biomedical-engineering-online.biomedcentral.com/articles/supplements/
volume-15-supplement-2.
Availability of data and material
Data and materials presented in this paper can be shared upon request.
Funding
Publication of this article was funded by Advanced Medical Instruments (Grant No. 015000514316003).
Published: 28 December 2016
Page 410 of 410Gu et al. BioMed Eng OnLine 2016, 15(Suppl 2):123
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
References
 1. Giridharan GA, Pantalos GM, Gillars KJ, Koenig SC, Skliar M. Physiologic control of rotary blood pumps: an in vitro 
study. ASAIO J. 2004;50:403–9.
 2. Boston JR, Antaki JF, Simaan MA. Hierarchical control of heart-assist devices. IEEE Robot Autom Ma. 2003;10:54–64.
 3. Arndt A, Nüsser P, Graichen K, Muller J, Lampe B. Physiological control of a rotary blood pump with selectable thera-
peutic options: control of pulsatility gradient. Artif Organs. 2008;32:761–71.
 4. Wu Y. Adaptive physiological speed/flow control of rotary blood pumps in permanent implantation using intrinsic 
pump parameters. ASAIO J. 2009;55:335–9.
 5. Chang Y, Gao B. A global sliding mode controller design for an intra-aorta pump. ASAIO J. 2010;56:510–6.
 6. Moscato F, Arabia M, Colacino FM, Naiyanetr P, Danieli GA, Schima H. Left ventricle afterload impedance control by 
an axial flow ventricular assist device: a potential tool for ventricular recovery. Artif Organs. 2010;34:736–44.
 7. Vollkron M, Schima H, Huber L, Benkowski R, Morello G, Wieselthaler G. Development of a reliable automatic speed 
control system for rotary blood pumps. J Heart Lung Transplant. 2005;24:1878–85.
 8. Song Z, Gu K, Gao B, Wan F, Chang Y, Zeng Y. Hemodynamic effects of various support modes of continuous flow 
LVADs on the cardiovascular system: a numerical study. Med Sci Monit. 2014;20:733–41.
 9. Gao B, Nie LY, Chang Y, Zeng Y. Physiological control of intraaorta pump based on heart rate. ASAIO J. 2011;57:152–7.
 10. Chang Y, Gao B, Gu KY. A model-free adaptive control to a blood pump based on heart rate. ASAIO J. 2011;57:262–7.
 11. Gao B, Gu KY, Zeng Y, Chang Y. An anti-suction control for an intra-aorta pump using blood assistant index: a 
numerical simulation. Artif Organs. 2011;36:275–90.
 12. Gao B, Chang Y, Gu KY, Zeng Y, Liu YJ. Baroreflex sensitivity controller by intra-aortic pump: a potential benefit for 
heart recovery. ASAIO J. 2012;58:197–203.
 13. Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, et al. Reversal of severe heart failure with a continu-
ous-flow left ventricular assist device and pharmacologic therapy: a prospective study. Circulation. 2011;123:381–90.
 14. Mahmood MN, Fresiello L, Di Molfetta A, Ferrari G. A modeling tool to study the combined effects of drug adminis-
tration and LVAD assistance in pathophysiological circulatory conditions. Int J Artif Organs. 2014;37:824–33.
 15. Gu K, Chang Y, Gao B, Wan F, Loisance D, Zeng Y. Development of ventricular assist devices in China: present status, 
opportunities and challenges. Eur J Cardiothorac Surg. 2014;46:179–85.
 16. Kelly JG, Omalley K. Clinical pharmacokinetics of the newer ACE inhibitors. Clin Pharmacokinet. 1990;19:177–96.
 17. Macfadyen RJ, Meredith PA, Elliott HL. Differential effects of ACE inhibiting drugs: evidence for concentration-, dose- 
and agent-dependent responses. Clin Pharmacol Ther. 1993;53:622–9.
 18. Gao B, Gu KY, Zeng Y, Liu Y, Chang Y. A blood assist index control by intraaorta pump: a control strategy for ventricu-
lar recovery. ASAIO J. 2011;57:358–62.
 19. Hu LG. Study on the pharmacokinetics and bioequivalence of captopril. Changchun: Jilin University; 2005.
 20. Gu KY, Chang Y, Gao B, Liu Y, Zhang Y, Wan F. Lumped parameter model for heart failure with novel regulating 
mechanisms of peripheral resistance and vascular compliance. ASAIO J. 2012;58:223–31.
 21. Vermeirssen V, Van Camp J, Verstraete W. Optimisation and validation of an angiotensin-converting enzyme inhibi-
tion assay for the screening of bioactive peptides. J Biochem Biophys Methods. 2002;51:75–87.
 22. Maybaum S. Cardiac recovery during continuous-flow left ventricular assist device support some good news from 
across the Atlantic. Circulation. 2011;123:355–7.
 23. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, et al. Left ventricular assist device and drug therapy for 
the reversal of heart failure. N Engl J Med. 2006;355:1873–84.
 24. Karantonis DM, Lim E, Mason DG, Salamonsen RE, Ayre PJ, Lovell NH. Noninvasive activity-based control of an 
implantable rotary blood pump: comparative software simulation study. Artif Organs. 2010;34:34–45.
 25. Viecili PR, Pamplona D, Park M, Silva SR, Ramires JA, Da Luz PL. Antagonism of the acute hemodynamic effects of 
captopril in decompensated congestive heart failure by aspirin administration. Braz J Med Biol Res. 2003;36:771–80.
